Back to Treatments

Treatment

Glecaprevir/Pibrentasvir

1
Conditions
3
Trials
8,000
Participants
70%
Average Safety

Condition Evidence

Acute hepatitis C

3 trials · 8,000 participants

99% effectiveness · 70% safety
Glecaprevir/Pibrentasvir | DFDA